Cybin Inc.

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-06-24 pm EDT			5-day change	1st Jan Change
7.840 ^USD	+5.80%		+1.69%	-11.11%

Jun. 13	Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	CI
Jun. 13	Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	RE

Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder

Published on 05/08/2025 at 07:33

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Cybin Inc.

Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	Jun. 13	CI
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	Jun. 13	RE
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments	Jun. 03	MT
Cybin Inc. - Special Call	May. 29
Cybin Says Thermo Fisher Scientific to Offer US-Based Manufacturing for Its Depressive Disorder Program	May. 15	MT
Cybin Inc. Announces Additional U.S. Patent Supporting Its Cyb003 Therapy Program in Phase 3 Development for Major Depressive Disorder	May. 08	CI
Cybin Announces Additional U.S. Patent Supporting Its CYB003 Breakthrough Therapy Program In Phase 3 Development For Major Depressive Disorder	May. 08	RE
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025	Apr. 23	RE
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003	Apr. 23	CI
Cybin Partners With Osmind to Support Psychiatry Program Pipeline	Apr. 21	MT
Cybin Inc. Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs	Apr. 21	CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	Feb. 10	CI
Cybin, Segal Trials Collaborate to Advance Major Depressive Disorder Treatment	Jan. 15	MT
Cybin Launches Strategic Clinical Site Partnerships to Support Paradigm, A Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder	Jan. 15	CI
Cybin Inc. - Special Call	Dec. 11
Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year	Nov. 18	MT
Cybin Inc. - Special Call	Nov. 18
Cybin Reports Positive Phase 2 Data for Cyb003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder	Nov. 18	CI
Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	Nov. 13	CI
Cybin Initiates PARADIGM Multinational Pivotal Phase 3 Program Evaluating Cyb003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results	Nov. 13	CI
Cybin Inc. - Special Call	24-10-08
Cybin Inc. Announces Executive Appointments	24-10-01	CI
Cybin Inc.(NYSEAM:CYBN) added to S&P Global BMI Index	24-09-22	CI
Cybin Inc. Provides Corporate Update on Upcoming Clinical Milestones	24-09-20	CI
Cybin Inc. - Shareholder/Analyst Call	24-08-27

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-06-24 - Q4 2025 Earnings Release (Projected)

More about the company